Skip to main content
. Author manuscript; available in PMC: 2015 Aug 18.
Published in final edited form as: Cancer Cell. 2009 Mar 3;15(3):232–239. doi: 10.1016/j.ccr.2009.01.021

Figure 2. Short-Term Sunitinib Treatment Increases Spontaneous Metastasis and Decreases Survival after Removal of Primary Human Xenograft Tumors.

Figure 2

(A) Orthotopically grown 231/LM2-4LUC+ tumors were surgically removed, and SCID mice were treated daily with vehicle (group A) or short-term sunitinib therapy (group B). Biweekly quantification of bioluminescence showed accelerated tumor growth and increased spontaneous metastasis in group B compared with group A. Data are presented as mean ± SD.

(B) Representative bioluminescence images visualizing tumor cells before and after primary tumor resection (days 5 and 30 after resection).

(C) Kaplan-Meier survival curves of the corresponding mice show significantly decreased median survival in group B (log-rank test, p = 0.0024) compared with group A. 0.001 < **p < 0.01.

(D) Resected tumors were weighed prior to sorting into groups A and B to ensure equal tumor burden between groups. Sunitinib dose and treatment schedule were performed as illustrated in (A).